Using Mukbang to Improve Appetite, Nutritional Status and Quality of Life in Children With Cancer
ConditionChildren With Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-18
SponsorWei XIA, PhD
About this trial
This study aims to use a two arms randomized clinical trial study to evaluate the effectiveness of the effective constituent of Mukbang in helping children with cancer hospitalized for radiotherapy and chemotherapy to improve their appetite, nutritional status and quality of life.
Eligibility criteria
Qualifiers
Aged between 6 to 18 years old;
Children in accordance with the guidelines for the Diagnosis and Treatment of 12 Diseases related to hematologic diseases and malignant tumors (2021 version) issued by the General Office of the National Health Commission;
At least experience one full cycle of chemotherapy;
Children with moderate or higher symptoms of decreased appetite were screened for a list of treatment-related symptoms.
Disqualifiers
Children with serious cardiopulmonary disease, infection, organ damage, or genetic metabolic disease, immune deficiency disease, mental illness;
Children with eye or ear dysfunction that prevents them from watching and listening to videos.
Trial design
Treatments tested in this trial
- Active Ingredient Mukbang
- General short videos
Treatment groups
124 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wei XIA, PhD
Lead sponsor
Sun Yat-sen University
Sponsor institution
Source ClinicalTrials.gov